Skip to main content
. 2019 Mar 19;10(23):2237–2251. doi: 10.18632/oncotarget.26787

Figure 7. SAB298 and UM-164 inhibit SFK activity but have opposite effects on ERK and p38.

Figure 7

(A) Western blot showing common inhibition of SFK (pSFK Y416) in YUSIV, 501 mel and YUROB melanoma cells in response to the two inhibitors, but pERK was inhibited only in response to UM-164 (pERK T202/Y204). (B) stimulation of pp38 T180/Y182 in YUSIV melanoma cells incubated for increasing periods of time with SAB298. (C) Trametinib, but not SAB298, inhibits pp38 T180/Y182.